Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
SEATTLE, WA--(Marketwired - May 10, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company, today announced that it has received the second positive interim review on its Phase 1 study of endoxifen, which is an active …